Replies to post #175676 on Biotech Values

[zipjet]

HCV - GILD etc

The gating issue has been obvious.

Treating MD's have warehoused the HCV patients.

What multiple do you apply to earnings that peak early and decline over say 5 years to a fraction of the early results?

Prevalence will drop like a rock in the US.